APO-DIVALPROEX 250 MG
VALPROIC ACID (DIVALPROEX SODIUM) : 250 MG · DIN 02239699 · APOTEX INC
Health Canada status: MARKETED
What is APO-DIVALPROEX?
APO-DIVALPROEX 250 MG contains VALPROIC ACID (DIVALPROEX SODIUM) : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02239699, held by APOTEX INC, supplied as TABLET (DELAYED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Dec-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-DIVALPROEX used for?
Sole or adjunctive therapy for simple/complex absence seizures and primary generalized seizures with tonic-clonic manifestations. Treatment of manic episodes associated with bipolar disorder.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02239699 |
|---|---|
| Brand name | APO-DIVALPROEX |
| Generic / active ingredient | VALPROIC ACID (DIVALPROEX SODIUM) : 250 MG |
| Manufacturer | APOTEX INC |
| Strength | 250 MG |
| Dosage form | TABLET (DELAYED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AG01 VALPROIC ACID |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Dec-2021 |
How is it administered?
Initial: 15 mg/kg/day, increasing by 5-10 mg/kg/day weekly. Max: 60 mg/kg/day. Acute mania: 250 mg TID. Swallow tablets whole; can be taken with food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text (refer to section 11).
How is it supplied?
125 mg: HDPE bottles of 100 tablets. 250 mg and 500 mg: Packaging details for these strengths were truncated in text.
Contraindications
Hypersensitivity; pregnancy (for bipolar; for epilepsy unless no alternative); women of childbearing potential (unless Pregnancy Prevention Program met); hepatic disease; mitochondrial disorders (POLG).
Warnings and precautions
Serious warnings for hepatotoxicity (especially <2 years), teratogenicity, neurodevelopmental risks from paternal exposure, life-threatening pancreatitis, and mitochondrial disease risks.
What can be used instead?
Other Canadian products sharing ATC code N03AG01 VALPROIC ACID. 17 of 70 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DIVALPROEX | 125 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02239698 |
| APO-DIVALPROEX | 500 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02239700 |
| APO-VALPROIC ACID | 250 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02238048 |
| DEPAKENE | 250 MG / 5 ML | SOLUTION | BGP PHARMA ULC | MARKETED | DIN 00443832 |
| EPIVAL | 125 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | DIN 00596418 |
| EPIVAL | 250 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | DIN 00596426 |
| EPIVAL | 500 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | DIN 00596434 |
| JAMP DIVALPROEX | 250 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02551152 |
| JAMP DIVALPROEX | 500 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02551160 |
| JAMP VALPROIC ACID ORAL SOLUTION | 250 MG / 5 ML | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02532441 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.